Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma

Clinical trial NCT07622940 · RECRUITING

Trial details

NCT number: NCT07622940
Sponsor: Beijing Biotech
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Recurrent or Metastatic Esophageal Adenocarcinoma Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease

Start date: 2026-03-02
Primary completion: 2027-03-14
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.